Antigenic regions for the detection of anti-toxoplasma gondii igm antibodies
AssigneesBiokit Research & Development S.L.U., Universitat Pompeu Fabra
InventorsRoser Llevadot Esquerda, Marta Palicio Herrero, Greta Ripoll Pastor, David Andreu Martínez
Life of this patent
Estimating the term…
Abstract
The present invention provides compounds, methods for their preparation, methods for their use and compositions containing them, which are suitable for industrial application in the pharmaceutical and diagnostic/prognostic field, particularly for the detection and diagnosis of Toxoplasma gondii infections, as well as for the treatment and prevention of said infections.
Claims20
1-16. (canceled)
An antigen comprising an antigenic region of Toxoplasma gondii, wherein the antigenic region of Toxoplasma gondii comprises one or more amino acid sequences of SEQ ID:
- PPPNXQEL, wherein X can be any of amino acids S or A, and wherein the antigen is capable of specifically binding to Toxoplasma gondii-specific IgM antibodies.
The antigen of claim 1, wherein the antigenic region of Toxoplasma gondii comprises two or more amino acid sequences of SEQ ID:
- PPPNXQEL, wherein X can be any of amino acids S or A, and wherein the C-terminus of each amino acid sequence is linked to the N-terminal of the subsequent amino acid sequence through a simple covalent bond or they may employ a flexible linker domain, or polypeptide linkers consisting of small amino acids.
The antigen according to claim 1, wherein the antigenic region comprises SEQ ID NO 1 (antigen 6c), and wherein this sequence is capable of specifically binding to Toxoplasma gondii-specific IgM antibodies and has a maximum length of 150 amino acids.
The antigen according to claim 1, wherein the antigenic region comprises SEQ ID NO 2 (6c*), and wherein this sequence is capable of specifically binding to Toxoplasma gondii-specific IgM antibodies and has a maximum length of 150 amino acids.
The antigen according to claim 1, wherein the antigenic region comprises SEQ ID NO 4 (6cO36c), and wherein this sequence is capable of specifically binding to Toxoplasma gondii-specific TgM antibodies and has a maximum length of 150 amino acids.
The antigen according to claim 1, wherein the antigen comprises the amino acid sequence of SEQ ID NO:
- SEQ ID NO:
- 7 (3a6c) wherein this sequence is capable of specifically binding to Toxoplasma gondii-specific IgM antibodies and has a maximum length of 150 amino acids.
The antigen according to claim 1, wherein the antigen comprises the amino acid sequence of SEQ ID NO 8 (6c3a), wherein this sequence is capable of specifically binding to Toxoplasma gondii-specific IgM antibodies and has a maximum length of 150 amino acids.
The antigen according to claim 1, wherein the antigen is a chimeric antigen comprising two or more different antigenic regions, one of these regions being a sequence selected from, SEQ ID:
- PPPNXQEL, wherein X can be any of amino acids S or A, and wherein the antigen is capable of specifically binding to Toxoplasma gondii-specific IgM antibodies or, PPPNXQEL, wherein X can be any of amino acids S or A, and wherein the C-terminus of each amino acid sequence is linked to the N-terminal of the subsequent amino acid sequence through a simple covalent bond, a flexible linker domain, or polypeptide linkers consisting of small amino acids.
The antigen according to claim 1, wherein the antigen is selected from the list consisting of SEQ ID NO:
- 7 (3a6c) or SEQ ID NO 8 (6c3a).
A method for detecting anti-T. gondii IgMs in a sample comprising contracting any one of the antigens according to claim 1 with the sample.
A kit comprising at least one antigen according to claim 1.
Dependencies are inferred from the claim text.